DK0568577T3 - Peroralt indgivelig lægemiddelform til behandling af centrale dopaminmangeltilstande - Google Patents

Peroralt indgivelig lægemiddelform til behandling af centrale dopaminmangeltilstande

Info

Publication number
DK0568577T3
DK0568577T3 DK92903405.6T DK92903405T DK0568577T3 DK 0568577 T3 DK0568577 T3 DK 0568577T3 DK 92903405 T DK92903405 T DK 92903405T DK 0568577 T3 DK0568577 T3 DK 0568577T3
Authority
DK
Denmark
Prior art keywords
weight
pct
parts
treatment
dopamine deficiency
Prior art date
Application number
DK92903405.6T
Other languages
Danish (da)
English (en)
Inventor
Udo Wenzel
G Weber
J Metzner
Alfred Daerr
Sabine Freitag
Frank-Ulrich Floether
Frank-Michael Albert
Margit Haase
Edith Leistner
Original Assignee
Isis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Pharma Gmbh filed Critical Isis Pharma Gmbh
Application granted granted Critical
Publication of DK0568577T3 publication Critical patent/DK0568577T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK92903405.6T 1991-01-23 1992-01-23 Peroralt indgivelig lægemiddelform til behandling af centrale dopaminmangeltilstande DK0568577T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4101873A DE4101873C2 (de) 1991-01-23 1991-01-23 Peroral applizierbare Arzneiform zur Behandlung zentraler Dopaminmangelzustände

Publications (1)

Publication Number Publication Date
DK0568577T3 true DK0568577T3 (da) 1997-06-30

Family

ID=6423528

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92903405.6T DK0568577T3 (da) 1991-01-23 1992-01-23 Peroralt indgivelig lægemiddelform til behandling af centrale dopaminmangeltilstande

Country Status (22)

Country Link
US (1) US5532274A (sv)
EP (1) EP0568577B1 (sv)
JP (1) JP3382940B2 (sv)
AT (1) ATE147264T1 (sv)
AU (1) AU658171B2 (sv)
BG (1) BG61677B1 (sv)
CA (1) CA2101164C (sv)
CZ (1) CZ280847B6 (sv)
DE (2) DE4101873C2 (sv)
DK (1) DK0568577T3 (sv)
EE (1) EE03016B1 (sv)
ES (1) ES2098496T3 (sv)
FI (1) FI101040B (sv)
GR (1) GR3022993T3 (sv)
LT (1) LT3659B (sv)
LV (1) LV11103B (sv)
NO (1) NO304638B1 (sv)
RO (1) RO114737B1 (sv)
RU (1) RU2114619C1 (sv)
SK (1) SK369292A3 (sv)
UA (1) UA27848C2 (sv)
WO (1) WO1992012710A1 (sv)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6756056B2 (en) * 1997-04-08 2004-06-29 Alan A. Rubin Treatment of Parkinson's disease and related disorders by novel formulations of the combination carbidopa-levodopa
FI109453B (sv) * 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaceutisk komposition
US6531153B2 (en) 2001-05-29 2003-03-11 Drugtech Corporation Composition with sustained release of levodopa and carbidopa
US20040213848A1 (en) * 2001-09-28 2004-10-28 Shun-Por Li Modified release dosage forms
US20040180086A1 (en) * 2002-10-11 2004-09-16 Zebunnissa Ramtoola Gastro-retentive levodopa delivery form
WO2005023185A2 (en) 2003-08-29 2005-03-17 Transform Pharmaceuticals, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
ES2360759T3 (es) * 2003-08-29 2011-06-08 Centocor Ortho Biotech Inc. Composiciones farmacéuticas y procedimiento de utilización de la levodopa y de la carbidopa.
US8815950B2 (en) * 2003-08-29 2014-08-26 Janssen Biotech, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
NZ560826A (en) * 2005-03-28 2009-06-26 Orexo Ab Composition comprising weak acid and particulate L-dopa useful in the treatment of parkinson's disease
US20070003621A1 (en) * 2005-06-23 2007-01-04 Spherics, Inc. Dosage forms for movement disorder treatment
US20070275060A1 (en) * 2005-08-05 2007-11-29 Osmotica Costa Rica Sociedad Anonima Extended release solid pharmaceutical composition containing carbidopa and levodopa
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
AU2007338631A1 (en) * 2006-12-22 2008-07-03 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
AU2008343787B2 (en) 2007-12-28 2014-01-30 Impax Laboratories, Llc Controlled release formulations of levodopa and uses thereof
EP2233131A1 (en) * 2009-03-23 2010-09-29 Laboratorios Lesvi, S.L. Pharmaceutical composition containing levodopa, entacapone and carbidopa
KR20130009553A (ko) * 2011-07-15 2013-01-23 한미약품 주식회사 몬테루카스트 또는 이의 약학적으로 허용가능한 염 및 레보세티리진 또는 이의 약학적으로 허용가능한 염을 함유하는 캡슐 제제
CN105658211A (zh) 2013-10-07 2016-06-08 怡百克制药公司 左旋多巴和/或左旋多巴的酯的粘膜粘附性、控制释放调配物和其用途
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
JP7066351B2 (ja) * 2017-08-18 2022-05-13 大原薬品工業株式会社 良好な徐放性を有する、レボドパ含有小型化錠剤
WO2020100933A1 (ja) * 2018-11-13 2020-05-22 日本酢ビ・ポバール株式会社 結合剤
JP6695013B1 (ja) * 2018-11-13 2020-05-20 日本酢ビ・ポバール株式会社 結合剤
WO2020100932A1 (ja) * 2018-11-13 2020-05-22 日本酢ビ・ポバール株式会社 結合剤
JP6694564B1 (ja) * 2018-11-13 2020-05-13 日本酢ビ・ポバール株式会社 結合剤
US20230148062A1 (en) * 2020-04-10 2023-05-11 Japan Vam & Poval Co., Ltd. Binder
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE631201C (de) * 1932-08-07 1936-06-16 Chemische Forschungs Gmbh Traegerstoff fuer Arzneimittel
DE748317C (de) * 1941-08-17 1944-12-19 Wacker Chemie Gmbh Verfahren zur Herstellung in Wasser zerfallender Faeden, Filme, Baender, Schlaeuche u. dgl. aus unvollstaendig verseiften Polyvinylalkoholen
US3584113A (en) * 1967-08-31 1971-06-08 Eisai Co Ltd Process for the production of medical preparations having sustained release of therapeutical effect
NL149372B (nl) * 1968-10-01 1976-05-17 Merck & Co Inc Werkwijze voor het bereiden van farmaceutische preparaten, alsmede de door toepassing daarvan verkregen gevormde voortbrengselen.
US3769424A (en) * 1970-10-01 1973-10-30 Merck & Co Inc Composition and method of treating dopamine deficiency in brain tissue
IE49522B1 (en) 1979-04-26 1985-10-16 Merrell Toraude & Co Alpha-halomethylaminoacids
DE3042916A1 (de) * 1979-06-01 1982-07-01 Joachim 7440 Nürtingen Dudzik Tablette
CA1218604A (en) * 1981-07-08 1987-03-03 Alec D. Keith Trinitroglycerol sustained release vehicles and preparations therefrom
US4424235A (en) * 1981-09-14 1984-01-03 Hoffmann-La Roche Inc. Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor
CH652025A5 (de) 1981-09-14 1985-10-31 Hoffmann La Roche Pharmazeutisches praeparat.
JPS5852219A (ja) * 1981-09-22 1983-03-28 Sumitomo Chem Co Ltd パ−キンソン病治療剤
EP0147780A3 (en) * 1984-01-03 1987-03-11 Merck & Co. Inc. Drug delivery device
US4927633A (en) * 1984-03-19 1990-05-22 Alza Corporation Dispenser for delivering drug to livestock
US4685918A (en) * 1985-02-01 1987-08-11 Merck & Co., Inc. Lipid osmotic pump
ZA889189B (en) * 1986-06-16 1989-08-30 Merck & Co Inc Controlled release combination of carbidopa/levodopa
NZ220599A (en) * 1986-06-16 1990-10-26 Merck & Co Inc Controlled release oral dosage formulation of carbidopa and levodopa
US4983400A (en) * 1986-06-16 1991-01-08 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
US4832957A (en) * 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
SE460947B (sv) * 1986-08-26 1989-12-11 Lejus Medical Ab En multiple-unit-dos komposition av l-dopa
US4892778A (en) * 1987-05-27 1990-01-09 Alza Corporation Juxtaposed laminated arrangement
US4940465A (en) * 1987-05-27 1990-07-10 Felix Theeuwes Dispenser comprising displaceable matrix with solid state properties
US4915949A (en) * 1987-07-13 1990-04-10 Alza Corporation Dispenser with movable matrix comprising a plurality of tiny pills
CA1331563C (en) * 1987-08-03 1994-08-23 Gaylen M. Zentner Device for the controlled release of drugs with donnan-like modulation by charged insoluble resins
US4946686A (en) * 1987-09-24 1990-08-07 Merck & Co., Inc. Solubility modulated drug delivery system
AU608891B2 (en) * 1987-09-24 1991-04-18 Merck & Co., Inc. Solubility modulated drug delivery device
DE3841955A1 (de) * 1987-12-31 1989-07-13 Asta Pharma Ag Synergistische kombination von decarboxylasehemmern und l-dopa-pellets
ATE81971T1 (de) * 1987-12-31 1992-11-15 Asta Medica Ag Synergistische kombination von decarboxylasehemmern und l-dopa-pellets.

Also Published As

Publication number Publication date
FI933304A0 (fi) 1993-07-22
CZ280847B6 (cs) 1996-04-17
US5532274A (en) 1996-07-02
LV11103B (en) 1996-06-20
SK278736B6 (sk) 1998-02-04
EE03016B1 (et) 1997-08-15
JPH06504543A (ja) 1994-05-26
WO1992012710A1 (de) 1992-08-06
ES2098496T3 (es) 1997-05-01
GR3022993T3 (en) 1997-07-30
AU1186892A (en) 1992-08-27
ATE147264T1 (de) 1997-01-15
NO932522D0 (no) 1993-07-09
AU658171B2 (en) 1995-04-06
BG61677B1 (bg) 1998-03-31
CA2101164C (fr) 2001-04-24
RU2114619C1 (ru) 1998-07-10
BG97894A (bg) 1994-04-29
RO114737B1 (ro) 1999-07-30
UA27848C2 (uk) 2000-10-16
CZ369292A3 (en) 1993-09-15
NO932522L (no) 1993-07-09
DE59207852D1 (de) 1997-02-20
LTIP555A (en) 1994-11-25
DE4101873A1 (de) 1992-07-30
NO304638B1 (no) 1999-01-25
FI101040B (sv) 1998-04-15
FI933304A (fi) 1993-07-22
EP0568577B1 (de) 1997-01-08
DE4101873C2 (de) 1993-12-09
SK369292A3 (en) 1998-02-04
EP0568577A1 (de) 1993-11-10
LT3659B (en) 1996-01-25
CA2101164A1 (fr) 1992-07-24
JP3382940B2 (ja) 2003-03-04
LV11103A (lv) 1996-04-20

Similar Documents

Publication Publication Date Title
DK0568577T3 (da) Peroralt indgivelig lægemiddelform til behandling af centrale dopaminmangeltilstande
IL117356A (en) Controlled release matrix and pharmaceutical compositions for oral administration containing it
GEP20043315B (en) Non-Peptide GnRH Agents, Methods For Their Preparation and Use Thereof
KR880000098A (ko) 콘드로이틴 설페이트 면역자극 조성물
AR028299A1 (es) Una composicion farmaceutica que comprende nateglinida, un proceso para su preparacion y el uso de dicha composicion para la preparacion de un medicamento para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con diabetes.
NZ244021A (en) Benzylthiazolidinedione derivatives, preparation and pharmaceutical compositions thereof
KR920702216A (ko) 아세틸 d-카르니틴의 녹내장 치료에의 용도
ES2157993T3 (es) Benzoilguanidinas, su preparacion y su uso en medicamentos.
KR960700054A (ko) 파킨슨씨 병 및 파킨슨 증후군의 치료에 리루졸의 이용(application of riluzole in the treatment of parkinson's disease and parkinsonian syndromes)
HRP20030046B1 (en) Pharmaceutical compositions for the treatment of mucositis, stomatitis and behcet's syndrome
RS50768B (sr) Režim doziranja i farmaceutska formulacija za urgentnu zaštitu
NO992944L (no) Virkestoffbµrer for avgivelse av apomorfin i munnhulen
CA2136404A1 (fr) Composition solide mucoadhesive, therapeutique ou hygienique, pour administration par application sur la muqueuse buccale ou nasale
DE59410151D1 (de) Feste Flupirtin enthaltende orale Darreichungsformen mit kontrollierter Wirkstoffabgabe
ATE315399T1 (de) Hemmung von systemischen infektionen in menschen und wirbeltieren mit ballaststoffen
FI955837A (sv) Förfarande för framställning av en oralt administrerbar, fast doseringsform innehållande diklofenak
KR920019350A (ko) 자기면역질환요법을 위한 약제조성물
FR2662942B1 (fr) Medicament immunostimulant a base de glycopeptidolipides polaires de mycobacterium chelonae.
KR920019365A (ko) 디리트로마이신을 함유하는 약학 제형
KR890007728A (ko) 진통제 제조방법
Farina et al. Antibacterial activity of Nicaraguan vegetal extracts used in folk medicine
ES2093515T3 (es) Aplicacion del riluzol como radio-restaurador.
JPS55133313A (en) Cholesterol-lowering agent
KR960021046A (ko) 카페익산을 포함하는 b형 간염 치료제
DK493887A (da) Buccal formulering